NanoDetection Technology and Oligomerix have executed an exclusive worldwide licensing agreement that grants NanoDetection rights to develop and commercialize diagnostic tests using a proprietary panel of nine tau antibodies discovered by Oligomerix.
Oligomerix retains therapeutic rights to the antibody portfolio. The antibodies are reported to differentiate distinct tau species, including cleavage-specific and conformationally altered forms within the filament core, enabling distinction between Alzheimer’s disease and related tauopathies such as Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration, while supporting quantitative characterization of protein aggregation.
NanoDetection has incorporated the antibody panel into its TRACE-Tau platform for use on its Luminorix instrument system with the Accuglo chemiluminescent assay architecture.
According to the company, analyses of multiple Alzheimer’s patient samples demonstrated detection and characterization of aggregated tau across several human sample types and support the translational relevance of the platform.
Validation in cerebrospinal fluid is described as promising and is being advanced in collaboration with the UMass Chan Medical School Morphology and SCOPE cores.
NanoDetection is based in Franklin, Ohio, and Oligomerix is headquartered in the Bronx, New York.
